Efgartigimod alfa - argenx
Alternative Names: ARGX-113; EFG PH20 SC; Efgartigimod - argenx; Efgartigimod alfa-fcab - argenx; efgartigimod PH20; efgartigimod PH20 SC; PH20 SC; VYVDURA; VYVGART; VYVGART HYTRULOLatest Information Update: 05 May 2024
At a glance
- Originator arGEN-X
- Developer argenx; Medison; ZAI Lab
- Class Anti-inflammatories; Antiarrhythmics; Immunoglobulin Fc fragments; Monoclonal antibodies; Skin disorder therapies; Urologics
- Mechanism of Action Neonatal Fc receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Myasthenia gravis
- Preregistration Chronic inflammatory demyelinating polyradiculoneuropathy; Idiopathic thrombocytopenic purpura
- Phase III Bullous pemphigoid; Graves ophthalmopathy; Myositis; Pemphigus
- Phase II Lupus nephritis; Membranous glomerulonephritis; Sjogren's syndrome; Tachycardia
- Clinical Phase Unknown Anti-neutrophil cytoplasmic antibody-associated vasculitis; Renal transplant rejection
- Preclinical Immune-mediated necrotising myopathy
Most Recent Events
- 30 Apr 2024 Argenx plans to initiate the phase III trial for Myasthenia Gravis in May 2024 (SC) (NCT06392386)
- 16 Apr 2024 Phase-III clinical trials in Myasthenia gravis (Treatment-experienced, In children, In adolescents, In adults, In the elderly) in USA (IV) (NCT06298552)
- 15 Apr 2024 Clinical trials in Anti-neutrophil cytoplasmic antibody-associated vasculitis at unknown location (Parenteral) (Argenx pipeline, April 2024).